Here are four things to know:
1. The statement alerts physicians and patients about understanding the risks and benefits associated with stem cell and biologic treatments for musculoskeletal joint conditions.
2. Specifically, the position statement reads: “surgeons should be cognizant of the risks, benefits, regulatory status and labeled indications of the products they use.”
3. AAOS also highlights “Orthopaedic Surgical Consent” and “Standards of Professionalism” guidelines in the position statement.
4. AAOS concludes the statement by calling on orthopedic surgeons and hospitals to contribute biologic treatment efficacy data to registries.
More articles on biologics:
Bone Biologics reports positive preclinical results for its spine growth factor: 4 insights
Fuse Medical to acquire CPM Medical Consultants — 5 takeaways
HSS’ Dr. Christopher Mendias earns $800k grant for stem cell research — 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
